SPECIAL NOTICE
88 -- Immuno-Compromised Mice Strains - FDA-RFP-1113768
- Notice Date
- 4/3/2013
- Notice Type
- Special Notice
- NAICS
- 112990
— All Other Animal Production
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- FDA-RFP-1113768
- Archive Date
- 5/1/2013
- Point of Contact
- Juana Quinteros, Phone: 3018276764
- E-Mail Address
-
Juana.Quinteros@fda.hhs.gov
(Juana.Quinteros@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Special Notice in MS Word Format. THIS IS NOT A REQUEST FOR QUOTATIONS. This is a notice of intent to award a sole source Firm Fixed-Price Contract (FFP) Indefinite Delivery Indefinite Quantity (IDIQ). The Food and Drug Administration's Office of Acquisition and Grant Services intends to issue a sole source award to Jackson Laboratories for multiple strains of severely immuno-compromised mice. Strains include: Stock #005557 (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) Stock #007799 (NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ Stock #000651 (BALB/cJ) Scientists within FDA performing humanized mouse research have utilized these specific proprietary strains of severely immune compromised mice that are only available from The Jackson Laboratory. Other vendors sell immune compromised mice; however, they are not the same genetic strain and have inherent risk associated with their use. This risk includes the need to repeat all preliminary studies with a new strain of mice, since they are not the biologically the same and would yield different results. This notice of intent is not a request for competitive proposals. The proposed action is for supplies for which the Government intends to solicit and negotiate with only one source under the authority of 41 U.S.C. 253(c)(1), FAR 6.302-1. The estimated dollar value for this action is not to exceed $150,000. This will result in a contract for a base year with two option years. The projected award date is April 30, 2013. Interested parties may submit a capability statement by April 16, 2013 for considerations by the agency. Responses must be sent to Juana Quinteros via email at juana.quinteros@fda.hhs.gov. All correspondence must reference FDA-RFP-1113768.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDA-RFP-1113768/listing.html)
- Place of Performance
- Address: 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, United States
- Zip Code: 20993
- Zip Code: 20993
- Record
- SN03027360-W 20130405/130403234350-71abe205c4a2c851eda2f28a9518707d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |